Vobarilizumab, CAS 1628814-88-9

Product Description: Vobarilizumab (ALX-0061) is an anti-IL-6R monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis[1][2][3].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Kerschbaumer A, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020 Jun;79(6):744-759. /[2]M. Van Roy, et al. FRI0021 Alx-0061, an anti-IL-6r nanobody® for therapeutic use in rheumatoid arthritis, demonstrates in vitro a differential biological activity profile as compared to tocilizumab. Ann Rheum Dis. 2013. 72 (3). /[3]Van Roy M, et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17(1):135.

CAS Number: 1628814-88-9

Molecular Weight: N/A

Compound Purity: 97.36

Research Area: Inflammation/Immunology

Solubility: 10 mM in DMSO

Target: Interleukin Related

• Artikelnummer: MEXHY-P99385-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99385-10
• Green Labware: Nein
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK